SUBSCRIBE
SUBSCRIBE

Humanetics

IN THE PRESS
BioMidwest
ONL Therapeutics Receives Phase II National Eye Institute Grant From National Eye Institute For Development Of Novel Retinal Disease Treatment
November 12, 2014
 · 
3 min read
BioMidwest
New Grant Enables Humanetics To Evaluate Potential Treatment For Erectile Dysfunction In Prostate Cancer Patients
July 9, 2014
 · 
1 min read
Business
Humanetics Enters Into Cooperative Research And Development Agreement With The U.S. Army Medical Research Institute of Chemical Defense
February 26, 2014
 · 
1 min read
BioMidwest
Humanetics Awarded Patent Enabling Oral Administration of Powerful Radioprotectant
October 15, 2013
 · 
1 min read
Business
Humanetics Awarded Contract With National Cancer Institute
October 3, 2012
 · 
1 min read
BioMidwest
Humanetics Announces Alzheimer’s Disease Patent Issuance
June 28, 2012
 · 
1 min read
Policy
Humanetics Awarded Exclusive Worldwide Licenses from Henry Ford Hospital Health System for Two Post-Exposure Medical Radiation Countermeasures
August 12, 2010
 · 
1 min read
BioMidwest
Patent Issued for Humanetics’ BIO 300 Radiation Countermeasure Drug
March 5, 2010
 · 
1 min read
Drug Development
Safety and Cognitive Stability Are Key Findings in Phase IIA Trial of New Alzheimer’s Disease Treatment from Humanetics
July 13, 2009
 · 
1 min read
Drug Development
Humanetics Completes Phase I Safety and Pharmacokinetic Trial for New Radiation Countermeasure
January 11, 2008
 · 
1 min read
Load More
JOBS